GE Healthcare unveils Chronicle to automate cell therapy manufacturing
GE Healthcare announced the launch of its Chronicle automation software, a digital platform designed to optimize complex cell therapy process development and manufacturing.
WHAT IT DOES
As the next generation development of the company’s my.Cryochain software, Chronicle offers a unified digital space to monitor all facility manufacturing operations and supply chain logistics, providing real-time data acquisition and notifications.
The automation software also provides electronic batch records, which trace every manufacturing step with automation to increase productivity, reinforce GMP compliance, and can also improve the security of patients’ samples through increased traceability.
ON THE RECORD
“Chronicle automation software was designed to meet the digital needs of academic researchers and large biotechnology companies and will help ensure increased patient access to life-saving therapies,” Catarina Flyborg, general manager of cell and gene therapy for GE Healthcare, said in a statement.
Flyborg explained the full potential of cell and gene therapies could not be realized without comprehensive digital solutions designed to optimize manufacturing processes, and which can also scale from process development to commercialization.
In addition, Chronicle capabilities include electronic Standard Operating Procedures (eSOPs), which are designed for specific processes to manage deviations, promote adherence to protocol, and provide guidance to ensure sensitive patient cells are handled appropriately.
The platform, built by cell therapy platform solution engineers, also integrates with the full range of GE instruments, as well as many third-party instruments, and is available immediately.
WHAT ELSE TO KNOW
Just this week GE Healthcare and Indi Molecular announced plans to collaborate on a diagnostic tool for clinical management of immunotherapy patients.
The companies will work together to develop non-invasive Positron Emission Tomography (PET) imaging agents (tracers) targeting CD8, focused on marking cytotoxic T lymphocytes, key predictors of immunotherapy response.
The potential ability of PET tracers to give a better understanding of a patient’s immune cell profile may provide an early indication of whether the patient is likely to respond to therapies, thereby enhancing clinical trial outcomes by improving the chances of immunotherapies successfully reaching the market.
Earlier this year GE Healthcare and Vanderbilt University Medical Center partnered on an AI-enabled precision medicine project, whereby Vanderbilt would leverage GE technology to improve its use of immunotherapy data for cancer treatment.
Nathan Eddy is a healthcare and technology freelancer based in Berlin.
Email the writer: firstname.lastname@example.org
Healthcare IT News is a HIMSS Media publication.